Coronary thrombolysis, conjunctive heparin infusion, and the effect on systemic thrombin activity.

Garabedian, Harry D.; Gold, H.K.

doi:10.1161/01.cir.85.3.1205

Cited by 10 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in accordance with several previous studies, demonstrating a short lasting, immediate increase in XIIa levels in patients with MI following treatment with streptokinase (SK) [6], tissue plasminogen activator (t-PA) [6] or recombinant tissue plasminogen activator (rtPA) [3]. It has been widely reported that thrombolytic drugs not only dissolve the clot, but also activate the complement and kinin system [4], [12][13][14] and increase thrombin generation [15][16][17][18]. These secondary effects are likely to be mediated by the activation of Factor XII, as shown by in-vitro experiments [6].…”

Section: Discussionsupporting

confidence: 91%

Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase

Pönitz

Pritchard²,

Grundt

et al. 2006

J Thromb Thrombolysis

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase

Pönitz

Pritchard²,

Grundt

et al. 2006

J Thromb Thrombolysis

View full text Add to dashboard Cite

show abstract

Contemporary Use of and Future Roles for Heparin in Antithrombotic Therapy

Gibaldi

Wittkowsky

1995

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Although heparin therapy is an established component of the prevention and treatment of thromboembolic disease, recent advances have resulted in improvements in the clinical use of this agent. Studies have shown that weight-based dosing influences significantly both the time to reach a therapeutic intensity of anticoagulation and the incidence of thromboembolic recurrence. It is now considered the standard of care. A growing understanding of the variability among activated partial thromboplastin time (aPTT) reagents and the influence of these differences on aPTT outcomes has led to the use of reagent-specific therapeutic ranges for heparin monitoring. Many practitioners now choose to adjust the therapeutic range to correspond to heparin serum concentrations of 0.2-0.4 U/mL rather than the more common practice of prolonging aPTT to 1.5-2.5 times the mean normal aPTT. Pharmaceutical companies have developed low molecular weight heparins to minimize adverse effects associated with unfractionated heparin. More specific thrombin inhibitors are also under investigation with the aim of improving clinical outcomes in coronary syndromes now treated with heparin. Low molecular weight heparins or specific thrombin inhibitors are unlikely to replace unfractionated heparin in the near future. Therefore, optimum dosing and appropriate monitoring of heparin are critically important in the management of thromboembolic disease.

show abstract

Challenge of Thrombolytic Therapy in Unstable Angina Pectoris

Venditto¹,

Ambrose²

1994

Developments in Cardiovascular Medicine

View full text Add to dashboard Cite

Coronary thrombolysis, conjunctive heparin infusion, and the effect on systemic thrombin activity.

Cited by 10 publications

References 23 publications

Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase

Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase

Contemporary Use of and Future Roles for Heparin in Antithrombotic Therapy

Challenge of Thrombolytic Therapy in Unstable Angina Pectoris

Contact Info

Product

Resources

About